Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM) is projected to reach $9.3b by 2034, ...

The disease primarily affects middle-aged women and has a poor long-term prognosis despite therapeutic advances.

Van Andel Institute scientists and collaborators have discovered a potential treatment target that may re-energize dysfunctional or "exhausted" immune cells in their fight against cancer.

The target is an immune checkpoint called PTGIR, which regulates the number and cancer-fighting powers of T cells, the ...

Researchers have discovered a potential treatment target that may re-energize dysfunctional or “exhausted” immune cells in ...

Van Andel Institute scientists and collaborators have discovered a potential treatment target that may re-energize dysfunctional or "exhausted" immune cells in their fight against cancer.

The introduction of sotatercept is driving a significant paradigm shift in pulmonary arterial hypertension (PAH) treatment, particularly regarding the role of prostacyclin pathway activators ...

Among patients with pulmonary arterial hypertension treated with selexipag, the 10-year survival rate was 60%, according to findings presented at the 2025 International Society for Heart and Lung ...

YUTREPIA is the first and only prostacyclin dry-powder formulation enabled by Liquidia’s proprietary PRINT™ technology, which yields uniform, free-flowing particles designed to enhance deep ...

Parenteral prostacyclin therapy benefits patients with PAH who are assessed as having an intermediate risk for death in 1 year.